H.C. Wainwright lowered the firm’s price target on Genfit (GNFT) to $7 from $9 and keeps a Buy rating on the shares. The company last week announced the discontinuation of VS-01 in acute on chronic liver failure following a case of peritonitis in the UNVEIL-IT study, the analyst tells investors in a research note. The firm updated Genfit’s model for the discontinuation and the company’s half year earnings report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNFT:
- Genfit’s 2025 Mid-Year Financial and Strategic Update
- GENFIT S.A. Releases Half-Year Financial Report for 2025
- GENFIT’s Strategic Shift and Financial Update for H1 2025
- GENFIT Discontinues VS-01 Program in ACLF to Focus on UCD
- Genfit SA: Strategic Positioning and Undervalued Potential in Biotechnology Sector